Guardant’s test analyzes circulating tumor DNA that is then used to identify patients with BRAF V600E-mutant metastatic colorectal cancer who may benefit from treatment with the Braftovi combo therapy ...

A blood-based colorectal cancer (CRC) screening test, SimpleScreen™, has shown a significant leap in performance, demonstrating high sensitivity for both malignant and advanced precancerous lesions ...

Pancreatic cancer is the third leading cause of cancer-related deaths, trailing behind lung cancer and colorectal cancer, a ...

Saga Diagnostics expanded the use of its ultrasensitive blood test to include detection of tiny amounts of colorectal cancer ...

The ctDNA test showed 79.2% sensitivity and 91.5% specificity for CRC detection in a diverse cohort. The study met primary end points but had limited sensitivity for advanced precancerous lesions.

FDA approves Guardant Health's blood test to help identify metastatic colorectal cancer patients eligible for targeted ...

The Food and Drug Administration on Monday approved Guardant Health’s blood test, called Shield, to screen for colon cancer, NBC News reported. The test isn't meant to replace colonoscopies, but is ...

Stool DNA testing climbed sharply after the pandemic began while colonoscopy and fecal immunochemical test use fell, a study of nearly 25 million privately insured Blue Cross Blue Shield beneficiaries ...

A study led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center found that while blood-based tests offer a more convenient option for colorectal cancer screening, only 49% of ...

Liquid biopsies have transformed cancer testing. These tests detect signs of cancer using a simple blood draw instead of removing tissue from the body. Traditional biopsies involve surgery, needles, ...

Active-duty service members and eligible family members now have access to blood test for colorectal cancer screening with no copay Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology ...